EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019–2023

Huizheng Zhang iD, Ping Wu iD, Wei Ye

PLOS One · 2026

DOI: 10.1371/journal.pone.0342301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Huizheng Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China. Hauptthemen laut MEDLINE: HIV-1, Drug Resistance, Viral, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Medical Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The emergence of drug resistance poses a major challenge to the long-term efficacy of antiretroviral therapy (ART) in managing HIV-1 infection. A comprehensive understanding of the prevalence and determinants of HIV-1 drug resistance mutations (DRMs) among patients with treatment failure in Chongqing, China, remains limited.

Objectives

This study sought to characterize the prevalence of HIV-1 DRMs and to identify factors associated with drug resistance in patients experiencing ART failure in Chongqing between 2019 and 2023.

Methods

We conducted a retrospective analysis of individuals living with HIV/AIDS who had received ART for at least six months and exhibited virologic failure(VF) (viral load(VL) > 1000 copies/mL). Genotypic resistance testing was performed on plasma samples. Associations between potential risk factors and the presence of DRMs were evaluated using univariate and multivariate logistic regression models.

Results

Of the 1,522 patients with ART failure included in the study, amplifiable partial pol and integrase (INT) gene sequences were obtained from 1,426 and 653 specimens, respectively. DRMs were identified in 66.55% (949/1,426) of the patients. The predominant HIV-1 subtype was CRF07_BC (50.14%). Class-specific DRM prevalence was highest for non-nucleoside reverse transcriptase inhibitors (NNRTIs) at 61.15%, followed by nucleoside reverse transcriptase inhibitors (NRTIs) at 44.60%, integrase strand transfer inhibitors (INSTIs) at 6.13%, and protease inhibitors (PIs) at 5.39%. The most commonly observed mutations were M184V/I (38.00%) for NRTIs, K103N/S/H (24.96%) for NNRTIs, and M46I (1.54%) for PIs. Multivariate analysis confirmed that lower baseline CD4 + T-cell counts and initiation of treatment with an NNRTI-based regimen were independently associated with the development of DRMs.

Conclusions

Our study reveals a high prevalence of HIV-1 drug resistance among patients with treatment failure in Chongqing, with low baseline CD4 + T-cell counts and NNRTI-based initial regimens identified as key risk factors. These findings underscore the urgency of optimizing first-line therapy by prioritizing dolutegravir (DTG)-based regimens, with protease inhibitor (PI)-based regimens as a practical alternative. Furthermore, we recommend implementing timely genotypic resistance testing, ideally within 4 weeks upon confirmed virologic failure, to guide effective regimen switching and curb the spread of drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Drug Resistance, ViralHIV InfectionsAnti-HIV AgentsHumansChinaFemaleRisk FactorsMaleTreatment FailureRetrospective StudiesAdultMutationViral LoadMiddle Aged

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
  • Department of Tuberculosis, Chongqing Public Health Medical Center, Chongqing, China.
  • Department of Physical Medicine and Rehabilitation, Chongqing General Hospital, Chongqing University, Chongqing, China.

ORCID-Profile: Huizheng Zhang, Ping Wu

Förderung

  • Chongqing Medical Scientific Research Project

Zitieren

APA

Zhang, H., Wu, P., & Ye, W. (2026). HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019–2023. PLOS One. https://doi.org/10.1371/journal.pone.0342301

Vancouver

Zhang H, Wu P, Ye W. HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019–2023. PLOS One. 2026. doi:10.1371/journal.pone.0342301

BibTeX
@article{Zhang2026,
  author = {Zhang, Huizheng and Wu, Ping and Ye, Wei},
  title = {HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019–2023},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0342301}
}
Kostenlos starten →